Search This Blog

Thursday, August 1, 2019

Syros Pharmaceuticals EPS misses by $0.05, beats on revenue

Syros Pharmaceuticals (NASDAQ:SYRS): Q2 GAAP EPS of -$0.47 misses by $0.05.
Revenue of $0.46M (+21.1% Y/Y) beats by $0.03M.
Press Release
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)